Status:
COMPLETED
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
Lead Sponsor:
R-Pharm
Conditions:
Solid Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
Eligibility Criteria
Inclusion
- confirmed diagnosis of a primary solid tumor
- measurable or non-measurable disease
- progressive disease
- men and women greater or equal to 18 years of age.
Exclusion
- women of child bearing potential who are not using birth control
- women who are pregnant or breast feeding
- women with a positive pregnancy test on enrollment
- patients with brain metastasis
- prior treatment with Ixabepilone
- known history of human immunodeficiency virus (HIV)
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00162136
Start Date
September 1 2005
End Date
July 1 2008
Last Update
November 2 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Maryland
Baltimore, Maryland, United States, 21201
2
The Cancer Institute Of New Jersey
New Brunswick, New Jersey, United States, 08901
3
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195